Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01439711 · ClinicalTrials.gov registry record · Phase 2

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

A Phase 2 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
108
Enrollment target
20
Study locations

NCT01439711 is a Phase 2 study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 108 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01439711, a Phase 2 study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
108 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how well letrozole works in treating women with ductal carcinoma in situ.

Conditions Studied

Breast Cancer

Interventions

  • PROCEDURE MRI
  • DRUG letrozole
  • PROCEDURE conventional surgery

Study Locations (20)

Delaware

  • Delaware Clinical and Laboratory Physicians PA - Newark
  • Helen F Graham Cancer Center - Newark
  • Medical Oncology Hematology Consultants PA - Newark
  • Regional Hematology and Oncology PA - Newark
  • Christiana Care Health System-Christiana Hospital - Newark

California

  • Cedars Sinai Medical Center - Los Angeles
  • Bay Area Tumor Institute - Oakland
  • UCSF Medical Center-Mount Zion - San Francisco

Kentucky

  • Saint Elizabeth Medical Center South - Edgewood
  • Saint Elizabeth Fort Thomas - Fort Thomas
  • Baptist Health Lexington - Lexington

Missouri

  • Saint Luke's Hospital of Kansas City - Kansas City
  • Missouri Baptist Medical Center - St Louis

Colorado

  • Exempla Saint Joseph Hospital - Denver

Iowa

  • University of Iowa/Holden Comprehensive Cancer Center - Iowa City

Maryland

  • Northwest Hospital Center - Randallstown

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2012-02
Est. Completion 2018-01
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01439711

The ClinicalTrials.gov registry entry for NCT01439711 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.

NCT01439711 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Delaware, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT01439711 about?

NCT01439711 is a clinical study titled "Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how well letrozole works in trea...

What is the current status of trial NCT01439711?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2012-02. Estimated completion is 2018-01.

What conditions does trial NCT01439711 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT01439711?

The interventions under investigation include: MRI (PROCEDURE), letrozole (DRUG), conventional surgery (PROCEDURE).

Who is sponsoring clinical trial NCT01439711?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01439711 being conducted?

This trial has 20 study locations across California, Colorado, Delaware, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.